|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-3-4
|
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) is an attractive target for the treatment of urothelial carcinoma, but a clinical response can be expected in only a small proportion of patients. The aim of this study was to define molecular markers of response to cetuximab therapy in a panel of urothelial carcinoma cell lines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cadherins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AdamLianaL,
pubmed-author:AroraAmeetaA,
pubmed-author:Bar-EliMenasheM,
pubmed-author:BlackPeter CPC,
pubmed-author:BrownGordon AGA,
pubmed-author:DinneyColin P NCP,
pubmed-author:InamotoTeruoT,
pubmed-author:McConkeyDavid JDJ,
pubmed-author:MunsellMark FMF,
pubmed-author:ShraderMarissaM,
pubmed-author:Siefker-RadtkeArlene OAO,
pubmed-author:TheodorescuDanD,
pubmed-author:WuXifengX
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1478-86
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18316572-Animals,
pubmed-meshheading:18316572-Antibodies, Monoclonal,
pubmed-meshheading:18316572-Antineoplastic Agents,
pubmed-meshheading:18316572-Blotting, Western,
pubmed-meshheading:18316572-Cadherins,
pubmed-meshheading:18316572-Carcinoma, Transitional Cell,
pubmed-meshheading:18316572-Cell Proliferation,
pubmed-meshheading:18316572-Cells, Cultured,
pubmed-meshheading:18316572-DNA Mutational Analysis,
pubmed-meshheading:18316572-Drug Resistance, Neoplasm,
pubmed-meshheading:18316572-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18316572-Gene Expression Profiling,
pubmed-meshheading:18316572-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18316572-Gene Silencing,
pubmed-meshheading:18316572-Humans,
pubmed-meshheading:18316572-In Situ Hybridization, Fluorescence,
pubmed-meshheading:18316572-Male,
pubmed-meshheading:18316572-Mice,
pubmed-meshheading:18316572-Mice, Nude,
pubmed-meshheading:18316572-NIH 3T3 Cells,
pubmed-meshheading:18316572-Neoplasm Invasiveness,
pubmed-meshheading:18316572-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:18316572-Phenotype,
pubmed-meshheading:18316572-Phosphorylation,
pubmed-meshheading:18316572-RNA, Small Interfering,
pubmed-meshheading:18316572-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18316572-Tumor Markers, Biological,
pubmed-meshheading:18316572-Urinary Bladder Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
|
|
pubmed:affiliation |
Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article
|
